The PRKN/METTL3/CLDN2 axis promotes colorectal cancer development through epigenetic mechanisms. [PDF]
Ren H, Wang M, Ma X, An L, Guo Y, Ma H.
europepmc +1 more source
m6A RNA methylation in sepsis-induced cardiomyopathy: direct cardiac mechanisms, emerging therapeutic targets, and translational gaps. [PDF]
Zhang F, Zhang L, Wang Y.
europepmc +1 more source
GPSM2 Promotes Pancreatic Cancer Progression Through METTL3-Mediated m6A Modification of YAP1 mRNA. [PDF]
Xiu J +9 more
europepmc +1 more source
Diverse roles of YTHDC1 in chromatin and blood cancers. [PDF]
Pernon B +12 more
europepmc +1 more source
Immunometabolic reprogramming in rheumatoid arthritis: the epitranscriptomic role of N6-methyladenosine in innate and adaptive immunity. [PDF]
Yang J, Wan L, Chen H, Li S, Zhou Y.
europepmc +1 more source
m6A-Mediated epitranscriptional reprogramming drives cardiac fibrosis by suppressing PGC-1α and boosting mitochondrial fission. [PDF]
Cao XY +13 more
europepmc +1 more source
The METTL3 inhibitor STM2457 suppresses gastric cancer progression by modulating m6A RNA modification. [PDF]
Sun H +13 more
europepmc +1 more source
RNA methylation in urological cancers: regulatory logic, biological functions, and clinical relevance. [PDF]
Peng J +17 more
europepmc +1 more source
The epitranscriptomic m6A RNA modification modulates the synapse in ageing and in a mouse model of synucleinopathy. [PDF]
Chopra A +8 more
europepmc +1 more source
N6-methyladenosine modification in the context of viral infection: from molecular mechanism to therapeutic potential. [PDF]
Wu X, Deng Z, Li Y, Shi C.
europepmc +1 more source

